MaxCyte has agreed to buy Akron Bio from affiliates of Arcline Investment Management for US$151.8m in cash, shares and deferred payments, the Nasdaq-listed company said on 10 November 2026.
Why MaxCyte, Inc. is buying Akron BioProducts LLC (Akron Bio)
Akron supplies GMP-grade reagents and ancillary materials used from cell expansion through cryopreservation, and its products are embedded in customers' validated processes and regulatory filings. MaxCyte said the deal would nearly double its revenue base, add recurring commercial-stage revenue and create a combined portfolio supporting five approved therapies.
Deal terms and financing
Akron is expected to generate about US$28m of revenue and US$7m–8m of EBITDA in 2026. MaxCyte's 10-Q breaks the price into about US$105m in cash at closing, 20.6m new shares (about US$26.8m at the 9 November price) and US$20m of deferred payments.
Regulatory approvals and timing
The transaction is expected to close before the end of 2026, subject to customary closing conditions.
Market context
MaxCyte shares fell more than 10% on the day, Seeking Alpha reported. Arcline acquired a majority interest in Akron in 2019.
